ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Ono Pharmaceutical Co., Ltd.

Business Summary

Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2021 JPYUSD
Gross Profit221,097M2,084.69M
Operating income92,097M868.36M
Income before tax100,886M951.23M
Net income75,425M711.17M
Diluted EPS151.091.42
Dividends Per Share500.47
Total Assets746,842M6,758.75M
Total liabilities105,684M956.41M
Total equity635,547M5,751.55M
Operating cash flow73,977M697.51M
Currency in JPYCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 244,797M 261,836M 288,634M 292,420M 309,284M
Gross Profit 177,884M 194,743M 202,772M 210,874M 221,097M
Operating income 59,718M 59,569M 64,764M 79,181M 92,097M
Income before tax 74,540M 63,922M 65,141M 79,696M 100,886M
Net income 55,793M 50,284M 51,539M 59,704M 75,425M
EBITDA 67,539M 68,782M 75,385M 93,386M 107,917M
Diluted EPS 105.26 96.99 100.23 118.45 151.09
Dividends Per Share 40 45 45 45 50
Total Assets 617,461M 609,226M 655,056M 673,444M 746,842M
Total liabilities 92,118M 79,012.59M 92,320M 105,422M 105,684M
Total equity 519,110M 524,390M 557,350M 562,484M 635,547M
Operating cash flow 74,450M 15,727M 66,774M 74,157M 73,977M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 2,260.62M 2,362.44M 2,602.77M 2,689.51M 2,916.19M
Gross Profit 1,642.70M 1,757.09M 1,828.50M 1,939.50M 2,084.69M
Operating income 551.47M 537.46M 584.01M 728.26M 868.36M
Income before tax 688.35M 576.74M 587.41M 733.00M 951.23M
Net income 515.23M 453.69M 464.75M 549.12M 711.17M
EBITDA 623.70M 620.59M 679.78M 858.91M 1,017.53M
Diluted EPS 0.97 0.87 0.90 1.08 1.42
Dividends Per Share 0.36 0.40 0.40 0.41 0.47
Total Assets 5,541.24M 5,728.49M 5,918.20M 6,238.19M 6,758.75M
Total liabilities 826.68M 742.94M 834.07M 976.53M 956.41M
Total equity 4,658.61M 4,930.79M 5,035.46M 5,210.35M 5,751.55M
Operating cash flow 687.52M 141.89M 602.13M 682.05M 697.51M

Valuation Measures

Mar 2021
Operating margin29.77%
Profit margin24.38%

Key executives

  • President & Representative Director: Gyo Sagara
  • Managing Executive Officer & GM-Research: Toichi Takino
  • Executive Officer & Manager-NV Strategy Planning: Shozo Matsuoka
  • Director & Managing Executive Officer: Isao Ono
  • Director & Senior Managing Executive Officer: Kei Sano


  • Wellington Management Co. LLP (6.5%)
  • Ono Pharmaceutical Co., Ltd. (5.5%)
  • Meiji Yasuda Life Insurance Co. (3.5%)
  • Ono Shogakukai Foundation (3.1%)
  • Kakumeiso Co. Ltd. (3.0%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (2.9%)
  • Nomura Asset Management Co., Ltd. (2.9%)
  • The Vanguard Group, Inc. (2.0%)
  • Mitsubishi UFJ Financial Group, Inc. (1.6%)
  • MS&AD Insurance Group Holdings, Inc. (1.5%)

Contact Details

  • Website:
  • Address: 1-8-2 Kyutaromachi, Chuo-Ku, Osaka, 541-8564, Japan
  • Phone: +81.6.6263.5670

Related Companies

  • Ono Venture Investment, Inc.
  • Ono Pharma Taiwan Co., Ltd.
  • Ono Pharma Korea Co., Ltd.
  • Ono Pharma UK Ltd.
  • Ono Pharma USA, Inc.
  • Ono Shogakukai Foundation


  • Aprea Therapeutics, Inc.
  • Qurient Co., Ltd.
  • Vaxcell-Bio Therapeutics
  • CHO Pharma, Inc.
  • Tempest Therapeutics, Inc.
  • VistaGen Therapeutics, Inc.
  • Onxeo SA
  • Annexon, Inc.
  • BioLineRX Ltd.
  • PharmaEssentia Corp.
  • TiumBio Co., Ltd.
Last Updated on 26 Nov, 2021

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more